| Opportunity ID: |
319479 |
| Opportunity Number: |
CDC-RFA-GH20-2013 |
| Opportunity Title: |
Scaling Up High-Impact HIV Prevention, Testing and Treatment Models in Central America under the President's Emergency Plan for AIDS Relief (PEPFAR) |
| Opportunity Category: |
Discretionary |
| Opportunity Category Explanation: |
|
| Funding Instrument Type: |
Cooperative Agreement |
| Category of Funding Activity: |
Health |
| Category Explanation: |
|
| CFDA Number(s): |
93.067 |
| Eligible Applicants: |
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: |
|
| Agency Code: |
HHS-CDC-CGH |
| Agency Name: |
Department of Health and Human Services
Centers for Disease Control – CGH |
| Posted Date: |
Aug 13, 2019 |
| Last Updated Date: |
Aug 19, 2019 |
| Estimated Synopsis Post Date: |
Sep 18, 2019 |
| Fiscal Year: |
2020 |
| Award Ceiling: |
$0 |
| Award Floor: |
$0 |
| Estimated Total Program Funding: |
$0 |
| Expected Number of Awards: |
2 |
| Description: |
The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $5,000,000 for Year 1, subject to the availability of funds. This NOFO will support Ministries of Health and other stakeholders in Central America to introduce and/or scale up high-impact, WHO-recommended site-level HIV interventions. Key HIV prevention and diagnosis activities include index testing, differentiated service modalities at key population testing facilities, self-testing, pre-exposure prophylaxis (PreP), rapid recency testing and response to clusters of recent transmission, and linkage to treatment for newly diagnosed individuals. Key HIV treatment activities include linkage to care registries, early treatment initiation, differentiated service delivery models, opportunistic infection diagnosis and treatment, lost-to follow-up reengagement, quality assurance in viral load networks, and drug resistance monitoring. Expected outcomes related to the First 95 (Reach-Diagnose-Link) include an increased access to HIV testing and yield among key populations and index case partners, an improved public health response to active transmission clusters, and consistently high (>95%) linkage to treatment. For the second and third 95 (Treat-Retain-Virally Suppress), expected outcomes include increased early treatment initiation, retention and adherence, improved access to viral load testing and HIV drug resistance monitoring, and sustained viral suppression. The NOFO also includes above-site technical assistance to advance the integration of PEPFAR-supported strategies into national guidelines, manuals, and systems. |
| Version: |
3 |
| Modification Comments: |
Updated Post date and application due date. |
|
